FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

Key facts

Sponsor

Eli Lilly and Company

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

Eli Lilly and Company

Intervention

LOXO-435(drug)

Enrollment

535 target

Eligibility

18 years · All sexes

Timeline

2023 – 2027

Study locations (30)

• University of Arizona - Cancer Center, Tucson, Arizona, United States
• City of Hope, Duarte, California, United States
• University of California, Los Angeles (UCLA) - Division of Hematology-Oncology, Los Angeles, California, United States
• University of California - Irvine, Orange, California, United States
• University of California (UC) Davis Comprehensive Cancer Center, Sacramento, California, United States
• Stanford Medicine Cancer Center, Stanford, California, United States
• Advent Health, Orlando, Florida, United States
• Emory University Hospital, Atlanta, Georgia, United States
• The University of Chicago Medical Center (UCMC), Chicago, Illinois, United States
• Indiana University (IU) Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
• Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States
• Ochsner Clinic Foundation, New Orleans, Louisiana, United States
• Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, United States
• Massachusetts General Hospital, Boston, Massachusetts, United States
• Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Papillary renal cell carcinoma

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGNCT07586332
  INVESTIGATION OF THE GENETIC ETIOLOGY OF HERNIA SAC DEVELOPMENT IN MALE CHILDREN WITH UNDESCENDED TESTIS AND INGUINAL HERNIA
  Trakya University
• RECRUITINGNCT06956144
  Exploring the Clinical Application Value of CAIX-Targeted PET Imaging in Renal Cancer Patients
  The First Affiliated Hospital of Xiamen University
• RECRUITINGNCT06532422
  Study of Post-operative Complications After Laparoscopic Outpatient Nephrectomy
  GCS Ramsay Santé pour l'Enseignement et la Recherche
• RECRUITINGNANCT06542484
  The Real-world Treatment Satisfaction by Gefapixiant in RCC
  Nagoya City University
• RECRUITINGPHASE3NCT06467097
  Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma
  Samsung Medical Center
• RECRUITINGPHASE4NCT05805436
  Preop Laxatives in Robotic Urologic Surgery
  Chad R. Tracy
• ACTIVE NOT RECRUITINGPHASE1NCT05704985
  Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
  DEKA Biosciences
• ACTIVE NOT RECRUITINGPHASE2NCT05411081
  Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
  National Cancer Institute (NCI)

See all trials for Papillary renal cell carcinoma →